Recent work from our laboratories and others has shown that the LKB1 (STKII) tumor suppressor gene is frequently inactivated (through deletions or point mutations) in a wide variety of human cancers. Although Lkb1 inactivation facilitates tumor progression by enhanced invasion and metastasis and therefore appears to be an adverse prognostic feature, the mechanisms whereby Lkb1 deficiency promotes tumorigenesis are poorly understood at the molecular level. Our current understanding of Lkb1 suggests that it acts in part through the AMPK and mTOR pathway, but there is strong evidence that Lkb1 also acts through alternative parallel pathways that remain to be elucidated. Consequently, our ability to exploit Lkb1 deficiency to develop new targeted therapies is rather limited. This proposal represents a joint effort by four investigators with complementary areas of expertise and an established track record of productive collaborations in the areas of Lkb1 biology, mouse cancer models, and translational cancer research. We will refine faithful murine Lkb1-based genetic models we have already developed of pancreatic adenocarcinoma, non-small cell lung cancer, uterine cancer, and melanoma. These murine models will be used to 1) study the mechanisms whereby Lkb1 regulates tumor progression;2) identify biomarkers expressed by Lkb1-deficient cancers and explore their utility as predictors of adverse outcomes and therapeutic responses in humans, taking advantage of our existing banks for the above tumors;and 3) develop and test novel therapeutic agents and strategies against Lkb1-deficient cancers. These models will employ state-of-the-art conditional and somatic inactivation strategies, and combine Lkb1 deficiency with other established oncogenic driver events well-studied in the four laboratories. These efforts will leverage the unique strengths of the four participating institutions in molecular biology, small animal imaging, comparative pathology, pharmacology, and experimental therapeutics. This research will lead to an enhanced understanding of the role of Lkb1 inactivation in a variety of neoplasms, and translate this new understanding into novel predictive biomarkers and therapeutic approaches.

Public Health Relevance

Progress in the treatment of cancer will depend on the development of highly specific agents that target distinct signaling pathways, thereby minimizing the side effects associated with traditional agents (personalized medicine). By combining mouse models of cancer with studies of human cell lines and primary tumor samples, this research will enhance the identification of novel therapies effective against cancers harboring signature genetic lesions, and a Iso lead to tests to predict these therapeutic responses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA141576-05
Application #
8545704
Study Section
Special Emphasis Panel (ZCA1-SRLB-Q (M1))
Program Officer
Marks, Cheryl L
Project Start
2009-09-01
Project End
2014-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2013
Total Cost
$732,590
Indirect Cost
$73,011
Name
University of Texas Sw Medical Center Dallas
Department
Pathology
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Chen, Zhao; Akbay, Esra; Mikse, Oliver et al. (2014) Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res 20:1204-11
Baker, M D; Ezzati, M; Aloisio, G M et al. (2014) The small GTPase Rheb is required for spermatogenesis but not oogenesis. Reproduction 147:615-25
Sakamaki, Jun-Ichi; Fu, Accalia; Reeks, Courtney et al. (2014) Role of the SIK2-p35-PJA2 complex in pancreatic ?-cell functional compensation. Nat Cell Biol 16:234-44
Xu, Chunxiao; Fillmore, Christine M; Koyama, Shohei et al. (2014) Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 25:590-604
Zhu, Zehua; Aref, Amir R; Cohoon, Travis J et al. (2014) Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 4:452-65
Aguilera, Kristina Y; Rivera, Lee B; Hur, Hoon et al. (2014) Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. Cancer Res 74:1032-44
Hanna, Sara C; Krishnan, Bhavani; Bailey, Sean T et al. (2013) HIF1* and HIF2* independently activate SRC to promote melanoma metastases. J Clin Invest 123:2078-93
Herter-Sprie, Grit S; Kung, Andrew L; Wong, Kwok-Kin (2013) New cast for a new era: preclinical cancer drug development revisited. J Clin Invest 123:3639-45
Akbay, E A; Pena, C G; Ruder, D et al. (2013) Cooperation between p53 and the telomere-protecting shelterin component Pot1a in endometrial carcinogenesis. Oncogene 32:2211-9
Liu, Yan; Marks, Kevin; Cowley, Glenn S et al. (2013) Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov 3:870-9

Showing the most recent 10 out of 19 publications